Opendata, web and dolomites

SCAUT SIGNED

Ser-Col; from finger to laboratory; personalized and automated serum collection for laboratory diagnostics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SCAUT project word cloud

Explore the words cloud of the SCAUT project. It provides you a very rough idea of what is the project "SCAUT" about.

burden    population    standards    prior    diseases    finger    diagnostics    col    industry    performance    standardized    painless    groups    taxing    reg    drops    environment    decentralization    manufacturing    stable    2023    centrifuge    disease    validation    serum    reduces    centralized    clinically    separation    ultimately    463    cumulative    million    platform    realize    profit    2027    obtain    sampling    wasteful    version    optimal    ready    disposed    stick    incredibly    compatibility    storage    few    50    combines    simplifies    links    vulnerable    attract    infectious    safe    blood    finalize    cold    18    device    95    innovative    logistic    months    breaking    venipuncture    full    thereby    biohazardous    specimens    diagnostic    collected    analytical    waste    813    tube    investors    scaut    trained    urgent    engage    laboratories    adoption    incineration    automated    collection    replacing    clinical    market    created    healthcare    barriers    reducing    ser    validate    laboratory    professionals    commercialization    social    accelerate   

Project "SCAUT" data sheet

The following table provides information about the project.

Coordinator
LABONOVUM BV 

Organization address
address: ZIJAKKERTJE 2
city: LIMMEN
postcode: 1906 BE
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.scaut.info
 Total cost 3˙984˙850 €
 EC max contribution 2˙998˙374 € (75%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-EIC-FTI-2018-2020
 Funding Scheme IA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LABONOVUM BV NL (LIMMEN) coordinator 761˙687.00
2    BLOK SYSTEM SUPPLY BV NL (AMSTERDAM) participant 1˙540˙087.00
3    CENTRE HOSPITALIER UNIVERSITAIRE MONTPELLIER FR (MONTPELLIER) participant 453˙875.00
4    YEREVAN STATE MEDICAL UNIVERSITY AFTER MKHITAR HERATSI AM (YEREVAN) participant 242˙725.00

Map

 Project objective

95% of blood collected via venipuncture is not used for diagnostic measurements, and needs to be disposed as biohazardous waste by incineration, which is incredibly wasteful and taxing on our environment. In Europe, there is an urgent need for innovative approaches that engage vulnerable groups and increase access to infectious disease testing by breaking-down social and logistic barriers to healthcare. The decentralization of healthcare have created a need for a simple, safe, standardized and painless collection of serum specimens. The Ser-Col® is a novel serum separation device that simplifies and combines both blood collection and serum separation. With a few drops of blood from a finger stick, serum can be collected which is stable for several months prior to analysis of clinically relevant serum parameters, and thereby reducing biohazardous waste production by 50%. Ser-Col simplifies and reduces the cost of serum sampling by replacing the blood tube, trained personnel, cold storage, and centrifuge with a reliable and easy to use device that links target population to centralized diagnostics laboratories, ultimately leading to the long-term reduction of the burden of infectious diseases. The SCAUT consortium will scale up manufacturing to deliver a market ready version of the Ser-Col and validate its clinical performance against existing standards. To ensure market uptake the consortium will develop an automated serum processing platform for optimal compatibility with exciting laboratory diagnostic equipment and facilitate adoption of Ser-Col by healthcare professionals. This will accelerate commercialization, attract investors and to establish industry partnerships required to realize the full potential of the technology. The SCAUT project seeks to obtain €3 million to finalize the analytical and clinical validation and go-to-market of the Ser-Col® device. The estimated cumulative profit is €463.813 in 2023 increasing towards €18 million in 2027.

 Deliverables

List of deliverables.
Project website Websites, patent fillings, videos etc. 2020-01-30 08:24:10

Take a look to the deliverables list in detail:  detailed list of SCAUT deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SCAUT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SCAUT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

Bio-LP-1 (2020)

A novel rapid environmental test for the human pathogen Legionella

Read More  

PAV-DT (2019)

A disruptive technology that enables low cost real-time monitoring of road pavement condition by any ordinary vehicle circulating on the road, and automatically designs plans for predictive maintenance.

Read More  

De-RISC (2019)

De-RISC: Dependable Real-time Infrastructure for Safety-critical Computer

Read More